Publications by the researcher in collaboration with María Font Arellano (38)

2024

  1. Formulation Studies with Cyclodextrins for Novel Selenium NSAID Derivatives

    International Journal of Molecular Sciences, Vol. 25, Núm. 3

  2. Thermal characterization, polymorphism, and stability evaluation of Se-NSAID derivatives with potent anticancer activity

    Journal of Thermal Analysis and Calorimetry, Vol. 149, Núm. 3, pp. 1015-1028

2018

  1. Methylselenol release as a cytotoxic tool: A study of the mechanism of the activity achieved by two series of methylselenocarbamate derivatives

    Metallomics, Vol. 10, Núm. 8, pp. 1128-1140

2017

  1. Topological and quantum molecular descriptors as effective tools for analyzing cytotoxic activity achieved by a series of (diselanediyldibenzene-4,1-diylnide)biscarbamate derivatives

    Journal of Molecular Graphics and Modelling, Vol. 73, pp. 62-73

2016

  1. Novel heteroaryl selenocyanates and diselenides as potent antileishmanial agents

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 6, pp. 3802-3812

2015

  1. Assessment of β-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in L. major infected BALB/c mice

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 11, Núm. 8, pp. 2003-2012

  2. Molecular descriptors calculation as a tool in the analysis of the antileishmanial activity achieved by two series of diselenide derivatives. An insight into its potential action mechanism

    Journal of Molecular Graphics and Modelling, Vol. 60, pp. 63-78

2014

  1. A dihydroselenoquinazoline inhibits S6 ribosomal protein signalling, induces apoptosis and inhibits autophagy in MCF-7 cells

    European Journal of Pharmaceutical Sciences, Vol. 63, pp. 87-95

  2. Novel hybrid selenosulfonamides as potent antileishmanial agents

    European Journal of Medicinal Chemistry, Vol. 74, pp. 116-123

  3. Synthesis and antiproliferative activity of novel methylselenocarbamates

    European Journal of Medicinal Chemistry, Vol. 83, pp. 674-684

  4. Synthesis and antiproliferative activity of novel selenoester derivatives

    European Journal of Medicinal Chemistry, Vol. 73, pp. 153-166

2013

  1. Bisacylimidoselenocarbamates cause G2/M arrest associated with the modulation of cdk1 and chk2 in human breast cancer MCF-7 cells

    Current Medicinal Chemistry, Vol. 20, Núm. 12, pp. 1609-1619

  2. Structural variations on antitumour agents derived from bisacylimidoselenocarbamate. A proposal for structure-activity relationships based on the analysis of conformational behaviour

    European Journal of Medicinal Chemistry, Vol. 66, pp. 489-498

2012

  1. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies

    Current Medicinal Chemistry, Vol. 19, Núm. 25, pp. 4259-4288

  2. Novel structural insights for imidoselenocarbamates with antitumoral activity related to their ability to generate methylselenol

    Bioorganic and Medicinal Chemistry, Vol. 20, Núm. 17, pp. 5110-5116

  3. Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine: Synthesis and study of their potential cytotoxic activity in vitro

    European Journal of Medicinal Chemistry, Vol. 47, Núm. 1, pp. 283-298

2011

  1. Kinase regulation by sulfur and selenium containing compounds

    Current Cancer Drug Targets, Vol. 11, Núm. 4, pp. 496-523

  2. New insights into the structural requirements for pro-apoptotic agents based on 2,4-diaminoquinazoline, 2,4-diaminopyrido[2,3-d]pyrimidine and 2,4-diaminopyrimidine derivatives

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 9, pp. 3887-3899

  3. Selenium and clinical trials: New therapeutic evidence for multiple diseases

    Current Medicinal Chemistry, Vol. 18, Núm. 30, pp. 4635-4650

  4. Selenocyanates and diselenides: A new class of potent antileishmanial agents

    European Journal of Medicinal Chemistry, Vol. 46, Núm. 8, pp. 3315-3323